▶ SS-31 · SUBTOPIC · DOSING LITERATURE

SS-31 Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of SS-31. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for SS-31 reports the following route(s) of administration: Subcutaneous (clinical). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of SS-31.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for SS-31 of approximately ~3 hours plasma. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of SS-31. Refer to the original publication for full protocol detail.

Szeto HH, Schiller PW (2011) reports the SS-31 protocol used in Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury, published in J Am Soc Nephrol. See the source for the protocol-level dose range, frequency, and duration. link
Pfeiffer K, Gohil V, Stuart RA, et al. (2003) reports the SS-31 protocol used in Cardiolipin stabilizes respiratory-chain supercomplexes, published in J Biol Chem. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What is the half-life of SS-31?

Approximately 3 hours plasma in humans, sufficient for once-daily subcutaneous dosing in the Stealth clinical program.

▶ Side effects of SS-31?

Clinical trials report mostly mild injection-site reactions and occasional headache. The peptide has been well-tolerated across multiple Phase 2/3 trials.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 2–8 °C, 12+ months

Reconstituted · 2–8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Investigational. Stealth BioTherapeutics has submitted regulatory packages for elamipretide in Barth syndrome and dry AMD; full FDA approval not granted as of 2026-05.

WADA · Not listed on the WADA Prohibited List (2026).

◀ SS-31 OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19